Out Of Stock
AOD9604 (5mg) FRAG 176-191
$97.00
Growth Hormone peptide Fragment 176-191 is also known as HGH Frag 176-191 and AOD9604. It is the modified form of the tail end of the Human Growth Hormone (HGH) molecule, known as the C terminal region. It constitutes less than ten percent of the total size of the HGH molecule, which is the fat-reducing part. It doesn’t affect growth or insulin resistance.
It mimics the way natural Growth Hormone regulates fat metabolism but is 12.5 times stronger for weight loss. It does this without affecting blood sugar or growth observed with unmodified Growth Hormone in animal test subjects. Fragment 176-191 has been shown in studies to release fat specifically from obese fat cells but not from lean ones, reduces new fat accumulation in all fat cells, and enhances fat burning.
It has a short half-life with peak concentrations occurring around 15 minutes and no longer than 60 minutes after administration.
Out of stock
Email when stock available
Related products
-
Mechano Growth Factor (MGF) is a synthetically manufactured peptide that is an alternative splicing variant of Insulin-like Growth Factor-1 (IGF-1). It serves as a local tissue repair factor that responds to changes in physiological conditions or environmental stimuli inducing muscle cell proliferation. It may function as a neuroprotectant in brain ischemia seen in animal studies.
The level of growth hormone decreases when animals’ age. Several studies show that intensive exercise may stimulate the release of growth hormone in the presence of MGF. This peptide upregulates protein synthesis and activates satellite cells. It is a potent inducer of muscle hypertrophy in experiments.
It has a relatively short half-life of only a few minutes and is often modified to Pegylated-Mechano Growth Factor (PEG-MGF), increasing its stability.
$97.00$67.00 -
BPC-157 stands for Body Protection Compound. It is also known as Bepecin, PL 14736, and PL10. It is a synthetic stable gastric pentadecapeptide consisting of fifteen amino acids. It is a partial sequence of BPC that is isolated from the gastric juice of humans.
It is synthetic because it doesn’t share similarities with any natural gastric peptides. It is more stable than other peptides and withstands stomach acid degradation for at least 24 hours.
More research is needed to clarify whether BPC-157 has multiple mechanisms of action. Current research in animal test subjects, suggests BPC-157 influences several growth factors usually involved in angiogenesis (the production of blood vessels) and other factors involved in regeneration following damage.
In small rats, it experimentally accelerated the healing of different wounds in tissues such as tendons, ligaments, skeletal muscle, and bone. Currently, it is in a clinical trial for treating inflammatory bowel disease.
$97.00 -
Growth Hormone Releasing Peptide-2 is also known as Pralmorelin or KP-102. It is a new 2nd generation synthetic hexapeptide made up of 6 amino acids.
It is closely related to GHRP-6, a hexapeptide of an earlier generation, and shares many similar characteristics. However, it has a stronger growth hormone-releasing action than GHRP-6 based on a study on cultured pituitary cells in animal test subjects, which showed a 10-fold increase in GH secretion.
Studies on animal test subjects suggest that GHRP-2 рlауs а rоlе аѕ аn аgоnіѕt of ghrelin, thе rесеntlу-fоund gut рерtіdе. It stimulates growth hormone secretion, with a slight stimulator effect on Prolactin, ACTH, and Cortisol levels. It also reduces the impact of the hormone somatostatin, which impairs the natural release of growth hormone.
Consequently, GHRP-2 has been shown to increase growth hormone levels and enhances growth performance in animal test subjects.
$97.00$77.00 -
CJC-1295 is a synthetic analog of the Growth Hormone-Releasing Hormone. With a substitution of four amino acids, it is more resistant to proteolytic inactivation by dipeptidyl peptidase IV (DPP-IV). When combined with Drug Affinity Complex (DAC), it prolongs its half-life, as well as the duration of action in test subjects.
Studies in animals (rats, pigs, and dogs) show that serum IGF-I levels increase several days after a single administration of CJC-1295 with DAC. It sustained a dose-dependent stimulation of serum GH and IGF-I levels when injected into healthy subjects at intervals of 1-2 weeks.
It increases plasma levels of growth hormone from somatotropic cells in the pituitary gland of animal test subjects, without altering its pulsation. It doesn’t inhibit the effects of somatostatin.
$97.00 -
$97.00 -
$97.00$77.00
Reviews
There are no reviews yet.